{"id":112816,"date":"2021-04-28T09:00:00","date_gmt":"2021-04-28T09:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2865905"},"modified":"2021-04-28T09:00:00","modified_gmt":"2021-04-28T09:00:00","slug":"more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/","title":{"rendered":"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications"},"content":{"rendered":"<p><img decoding=\"async\" width=\"180\" height=\"180\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p>The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.<\/p>\n<p><strong><em>To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this <\/em><\/strong><em>&#8211; <\/em><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html\"><em>https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html<\/em><\/a><\/p>\n<p>The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:<\/p>\n<ul>\n<li>Type of payment of licensing agreements<\/li>\n<li>Upfront payments<\/li>\n<li>Milestone payments<\/li>\n<\/ul>\n<p>Type of protein degrader<\/p>\n<ul>\n<li>Degronimids<\/li>\n<li>PROTACs<\/li>\n<li>SARDs \/ SERDs<\/li>\n<li>Specific BET and DUB inhibitors<\/li>\n<li>Other protein degraders<\/li>\n<\/ul>\n<p>Therapeutic area<\/p>\n<ul>\n<li>Neurodegenerative disorders<\/li>\n<li>Oncological disorders<\/li>\n<li>Other therapeutic areas<\/li>\n<\/ul>\n<p>Route of administration<\/p>\n<ul>\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Other routes<\/li>\n<\/ul>\n<p>Key geographical region<\/p>\n<ul>\n<li>North America<\/li>\n<li>Europe<\/li>\n<li>Asia-Pacific<\/li>\n<\/ul>\n<p><strong>The <\/strong><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html\">Targeted Protein Degradation Market<\/a>: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 <strong>report features the following companies, which we identified to be key players in this domain:<\/strong><\/p>\n<ul>\n<li>Arvinas<\/li>\n<li>Captor Therapeutics<\/li>\n<li>Celgene<\/li>\n<li>Genetech<\/li>\n<li>Kymera Therapeutics<\/li>\n<li>Mission Therapeutics<\/li>\n<li>Progenra<\/li>\n<li>Radius Health<\/li>\n<li>Sanofi Genzyme<\/li>\n<li>Zenopharm<\/li>\n<\/ul>\n<p><strong>Table of Contents<\/strong><\/p>\n<ol>\n<li><strong> Preface<\/strong><\/li>\n<li><strong>Executive Summary<\/strong><\/li>\n<li><strong>Introduction<\/strong><\/li>\n<li><strong>Current Market Landscape<\/strong> <\/li>\n<li><strong> Company Profiles<\/strong><\/li>\n<li><strong> Clinical Trial Analysis<\/strong><\/li>\n<li><strong> KOL Analysis <\/strong><\/li>\n<li><strong> Publication Analysis<\/strong><\/li>\n<li><strong> Funding and Investment Analysis <\/strong><\/li>\n<li><strong>Partnerships and Collaborations <\/strong><\/li>\n<li><strong>Market Sizing and Opportunity Analysis<\/strong><\/li>\n<li><strong> Executive Insights<\/strong><\/li>\n<li><strong> Concluding Remarks<\/strong><\/li>\n<li><strong> Appendix 1: Tabulated Data<\/strong><\/li>\n<li><strong> Appendix 2: List of Companies and Organizations<\/strong><\/li>\n<\/ol>\n<p>To purchase a copy, please visit <a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html\">https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html<\/a><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/research\/\" rel=\"tag\">Research<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/protein\/\" rel=\"tag\">Protein<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/biotech\/\" rel=\"tag\">biotech<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/target\/\" rel=\"tag\">target<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/rootsanalysis\/\" rel=\"tag\">Rootsanalysis<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.rootsanalysis.com\/reports\/view_document\/protein-degradation-market\/289.html<\/a><br \/><b>Contact Information:<\/b><br \/>Gaurav Chaudhary gaurav.chaudhary@rootsanalysis.com Roots Analysis A430, 4th Floor, Bestech Business Towers, Sector 66, Mohali, India sales@rootsanalysis.com +1 (415) 800 3415 +44 (122) 391 1091 Web: https:\/\/www.rootsanalysis.com\/ LinkedIn: https:\/\/in.linkedin.com\/company\/roots-analysis Twitter: https:\/\/twitter.com\/RootsAnalysis<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/wire\/\" rel=\"category tag\">Wire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Gaurav Chaudhary<br \/> gaurav.chaudhary@rootsanalysis.com<br \/> Roots Analysis<br \/> A430, 4th Floor,<br \/> Bestech Business Towers, Sector 66, Mohali, India<br \/> sales@rootsanalysis.com<br \/> +1 (415) 800 3415<br \/> +44 (122) 391 1091<br \/> Web: https:\/\/www.rootsanalysis.com\/<br \/> LinkedIn: https:\/\/in.linkedin.com\/company\/roots-analysis<br \/> Twitter: https:\/\/twitter.com\/RootsAnalysis<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\">More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\">More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-112816","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications - Business\" \/>\n<meta property=\"og:description\" content=\"The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, [&hellip;] The post More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\",\"name\":\"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png\",\"datePublished\":\"2021-04-28T09:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/","og_locale":"en_US","og_type":"article","og_title":"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications - Business","og_description":"The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, [&hellip;] The post More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/","og_site_name":"Business","article_published_time":"2021-04-28T09:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/","url":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/","name":"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png","datePublished":"2021-04-28T09:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/04\/4671-roots-analysis-squarelogo-14685651750522028129-5.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/04\/28\/more-than-85-small-molecule-protein-degraders-are-currently-being-evaluated-for-the-treatment-of-various-disease-indications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/112816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=112816"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/112816\/revisions"}],"predecessor-version":[{"id":112817,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/112816\/revisions\/112817"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=112816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=112816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=112816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}